Pauline C.
- Country
- France
- Department
- Medical oncology
Research Overview
- ISIdE: Open label, multicentric, single-arm phase IIIB trial to evaluate the safety and efficacy of sacituzumab govitecan in triple negative metastatic breast cancer patients with a biomarker analysis.
- Phase III Study of AZD5335 Versus Mirvetuximab Soravtansine or Investigator's Choice Chemotherapy in Patients with FRα-High or FRα-Low Platinum-Resistant Epithelial Ovarian Cancer
- Phase 3 Multicenter Randomized Study of Trastuzumab Deruxtecan vs. Trastuzumab Emtansine in High-Risk HER2-Positive Breast Cancer with Residual Disease
Data & Insights
Has run more than one trial at 275 of 573 partner sites.
Specializations
Breast Cancer Research
Specializes in treating various forms of breast cancer, with particular emphasis on HER2-positive breast cancer and triple-negative breast cancer (TNBC) management.
- HER2/neu peptide treatments
- Neoadjuvant therapy approaches
- Advanced treatment protocols for high-risk patients
Works with novel therapeutic approaches including targeted antibody treatments and immunotherapy combinations.
Gynecologic Oncology
Focuses on treating advanced epithelial ovarian cancer and endometrial cancer, with expertise in developing personalized treatment strategies.
- MMR-deficient cancer therapies
- Chemotherapy optimization protocols
- Advanced surgical interventions
Implements innovative treatment combinations including immunotherapy and targeted biological agents.
Supportive Cancer Care
Addresses treatment-related complications with special attention to cisplatin-induced ototoxicity and other treatment side effects.
- Preventive interventions for hearing loss
- Quality of life management
- Treatment optimization strategies
Develops protocols to minimize treatment-related adverse effects while maintaining therapeutic efficacy.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.